AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25405570 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 1843
Study 25405570 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 1843
Study 25405570 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg
Number of subjects: 1843
Study 25405570 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/MPA 1.5 mg
Number of subjects: 1843
Study 25405570 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg and CE 0.625 mg/BZA 20 mg
Number of subjects: 1843
Study 25405570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1843
Study 23233662 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (24‐hour infusion of a 1 g/m2 dose or 4‐hour infusion of a 2 g/m2 dose)
Number of subjects: 1279
Study 23233662 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment
Number of subjects: 1279
Study 23233662 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate treatment
Number of subjects: 1279
Study 23233662 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment with 5 different regimens
Number of subjects: 1279
Study 21534706 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional event interpretation
Number of subjects: 131
Study 21534706 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunction interpretation
Number of subjects: 131
Study 21534706 — intervention group
Group type: EXPERIMENTAL
Intervention: Response times for conditional event interpretations
Number of subjects: 131
Study 19690242 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-Traction Method (STM)
Number of subjects: 28
Study 19690242 — intervention group
Group type: COMPARATOR
Intervention: Non-Skin-Traction Method (non-STM)
Number of subjects: 28
Study 16968805 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 0
Study 16968805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15466104 — intervention group
Group type: EXPERIMENTAL
Intervention: HEDIS criteria for persistent asthma
Number of subjects: 896
Study 15466104 — intervention group
Group type: COMPARATOR
Intervention: NHLBI criteria for persistent asthma
Number of subjects: 896
Study 15466104 — intervention group
Group type: EXPERIMENTAL
Intervention: HEDIS criteria sensitivity
Number of subjects: 896
Study 15466104 — intervention group
Group type: EXPERIMENTAL
Intervention: HEDIS criteria specificity
Number of subjects: 896
Study 15466104 — intervention group
Group type: EXPERIMENTAL
Intervention: HEDIS criteria sensitivity for children without daily controller medications
Number of subjects: 896
Study 15466104 — intervention group
Group type: EXPERIMENTAL
Intervention: HEDIS criteria specificity for children without daily controller medications
Number of subjects: 896
Study 11303163 — intervention group
Group type: EXPERIMENTAL
Intervention: End-inspiration removal (n = 52)
Number of subjects: 69
Study 11303163 — intervention group
Group type: COMPARATOR
Intervention: End-expiration removal (n = 50)
Number of subjects: 69
Study 9296937 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with symptoms of threatened abortion (6‐15 weeks)
Number of subjects: 128
Study 9296937 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who did not undergo miscarriage
Number of subjects: 128
Study 9296937 — intervention group
Group type: COMPARATOR
Intervention: Healthy women in the first trimester of uncomplicated pregnancy (6‐15 weeks)
Number of subjects: 128
Study 9296937 — intervention group
Group type: COMPARATOR
Intervention: Healthy not pregnant women
Number of subjects: 128
Study 8518377 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane-N2O
Number of subjects: 14
Study 8518377 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 14
Study 2446275 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI + activity mode pacing (RRP)
Number of subjects: 15
Study 2446275 — intervention group
Group type: EXPERIMENTAL
Intervention: RRP
Number of subjects: 15
Study 30503230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculus Rift virtual reality assessment in vestibular hypofunction group
Number of subjects: 41
Study 30503230 — intervention group
Group type: COMPARATOR
Intervention: Oculus Rift virtual reality assessment in control group
Number of subjects: 41
Study 26956025 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) group who walked at 60% VO2peak to expend ≈ 5 kcal/kgbw one hour following the high-fat meal (HFM)
Number of subjects: 39
Study 26956025 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) who remained sedentary during the postprandial period
Number of subjects: 39
Study 26400835 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP) induction dosing patterns
Number of subjects: 740
Study 26400835 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP induction trajectory bup6
Number of subjects: 740
Study 26400835 — intervention group
Group type: COMPARATOR
Intervention: BUP induction trajectory
Number of subjects: 740
Study 23261733 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine alone (Group A)
Number of subjects: 30
Study 23261733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and Cognitive Behavioral Therapy (CBT) (Group B)
Number of subjects: 30
Study 20518173 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat sensitive moxibustion
Number of subjects: 160
Study 20518173 — intervention group
Group type: COMPARATOR
Intervention: Traditional hanging moxibustion
Number of subjects: 160
Study 20518173 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 160
Study 18484250 — intervention group
Group type: EXPERIMENTAL
Intervention: Single leech application (n = 38)
Number of subjects: 113
Study 18484250 — intervention group
Group type: EXPERIMENTAL
Intervention: Double leech application (n = 35)
Number of subjects: 113
Study 18484250 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 113
Study 15930064 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention with special resources for therapy
Number of subjects: 1356
Study 15930064 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention with special resources for medication management
Number of subjects: 1356
Study 15930064 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 1356
Study 15930064 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1356
Study 14595996 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai Chi exercise (1-hour sessions, twice weekly for 6 weeks)
Number of subjects: 39
Study 10793607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 50 mg administered rectally 30 min before anaesthesia
Number of subjects: 0
Study 10793607 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 0
Study 8793254 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen LAT (40 mg b.d.)
Number of subjects: 137
Study 1740600 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplement of 560 +/- 16 kcal/day (17% energy from protein, 43% from carbohydrate, 40% from fat) during 12 weeks of resistance training.
Number of subjects: 11
Study 1740600 — intervention group
Group type: COMPARATOR
Intervention: No supplement during 12 weeks of resistance training.
Number of subjects: 11
Study 6442383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (OX) 45 mg
Number of subjects: 7
Study 6442383 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (D) 15 mg
Number of subjects: 7
Study 6442383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiazepam (ND) 15 mg
Number of subjects: 7
Study 6442383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6442383 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (D) 5 mg
Number of subjects: 7
Study 6442383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (OX) 15 mg
Number of subjects: 7
Study 6442383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiazepam (ND) 5 mg
Number of subjects: 7
Study 30418528 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/Immed-ART-12
Number of subjects: 311
Study 30418528 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/Immed-ART-24
Number of subjects: 311
Study 30418528 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/Def-ART
Number of subjects: 311
Study 30418528 — intervention group
Group type: EXPERIMENTAL
Intervention: HEU
Number of subjects: 311
Study 30114796 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized grating condenser zone plate (GCZP)
Number of subjects: 0
Study 27075905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12 intake of 1.5 μg/d (0.3, 9.7 μg/d); 60% consumed <2.4 μg/d.
Number of subjects: 286
Study 27075905 — intervention group
Group type: EXPERIMENTAL
Intervention: Household Hunger Scale measurement indicated moderate or severe hunger prevalence of 27%.
Number of subjects: 286
Study 27075905 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-source food score ranged from 0 to 30 item-d/wk.
Number of subjects: 286
Study 27075905 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age as a variable.
Number of subjects: 286
Study 24593269 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin
Number of subjects: 173
Study 24593269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 22313988 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer/Vitremer
Number of subjects: 60
Study 22313988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond/Durafill VS
Number of subjects: 60
Study 22313988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond/Z100
Number of subjects: 60
Study 22313988 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 20668330 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyanoacrylates applied every 3‐5 days for 3 months
Number of subjects: 150
Study 20668330 — intervention group
Group type: COMPARATOR
Intervention: Topical silicone gel applied twice a day for 3 months
Number of subjects: 150
Study 17603862 — intervention group
Group type: EXPERIMENTAL
Intervention: 904 Ga‐As laser CW, frequency 50 Hz, intensity 40 mW, energy density 2.4 J/cm(2) plus plyometric exercises
Number of subjects: 50
Study 17603862 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser plus plyometric exercises
Number of subjects: 50
Study 16123686 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom promotion program teaching technical use skills in workshops
Number of subjects: 498
Study 16123686 — intervention group
Group type: COMPARATOR
Intervention: Control group received a brief informational presentation about AIDS
Number of subjects: 498
Study 16123686 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom promotion program
Number of subjects: 498
Study 12049706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat but high complex carbohydrates diet (HCO)
Number of subjects: 72
Study 12049706 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (monounsaturated fat-enriched)
Number of subjects: 72
Study 12049706 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat-enriched (SAT) diet
Number of subjects: 72
Study 11281499 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol 2 mg and norethisterone acetate 1 mg
Number of subjects: 60
Study 11281499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9065535 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alcoholism
Number of subjects: 237
Study 9065535 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol 1 to 25 g/day
Number of subjects: 237
Study 9065535 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol 26 to 50 g/day
Number of subjects: 237
Study 9065535 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol 51 to 100 g/day
Number of subjects: 237
Study 9065535 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol 101 to 200 g/day
Number of subjects: 237
Study 9065535 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol >200 g/day
Number of subjects: 237
Study 8424288 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 75
Study 8424288 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% oxygen: 50% nitrous oxide
Number of subjects: 75
Study 8424288 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen: 70% nitrous oxide
Number of subjects: 75
Study 2870722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipecac-induced emesis
Number of subjects: 18
Study 2870722 — intervention group
Group type: COMPARATOR
Intervention: Gastric lavage
Number of subjects: 18
Study 29755621 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation increasing (EI) group
Number of subjects: 72
Study 29755621 — intervention group
Group type: COMPARATOR
Intervention: Baseline (BL) group
Number of subjects: 72
Study 29755621 — intervention group
Group type: EXPERIMENTAL
Intervention: No expectation intervention (NoEI) group
Number of subjects: 72
Study 29755621 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation decreasing (ED) group
Number of subjects: 72
Study 25127887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with additional monitoring by Tvis levels
Number of subjects: 64
Study 25127887 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control) treated conservatively
Number of subjects: 64
Study 22560916 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized AVD (AV Opt group)
Number of subjects: 51
Study 22560916 — intervention group
Group type: COMPARATOR
Intervention: Empiric AVD of 110 ms (AV Fixed group)
Number of subjects: 51
Study 22560916 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT (both groups)
Number of subjects: 51
Study 20530806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rises in haemoglobin (Hgb)
Number of subjects: 154
Study 20530806 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA) dose increases
Number of subjects: 154
Study 20530806 — intervention group
Group type: COMPARATOR
Intervention: Hgb deflect(neg) and ESA dose decreases
Number of subjects: 154
Study 17951095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glides (SNAGs)
Number of subjects: 34
Study 17951095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (detuned laser)
Number of subjects: 34
Study 12866834 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 5 months
Number of subjects: 80
Study 12866834 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 80
Study 12866834 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding (independent choice)
Number of subjects: 80
Study 12866834 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast examination
Number of subjects: 80
Study 11128667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 155
Study 11128667 — intervention group
Group type: EXPERIMENTAL
Intervention: MACTAR questionnaire
Number of subjects: 155
Study 8773423 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed structured pretreatment counseling
Number of subjects: 421
Study 8773423 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling
Number of subjects: 421
Study 1611971 — intervention group
Group type: EXPERIMENTAL
Intervention: Optec inlay
Number of subjects: 73
Study 1611971 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Ceram inlay
Number of subjects: 73
Study 1611971 — intervention group
Group type: EXPERIMENTAL
Intervention: Coltene composite inlay
Number of subjects: 73
Study 1611971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic inlays
Number of subjects: 73
Study 1611971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic and composite inlays
Number of subjects: 73
Study 29506743 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14236
Study 29506743 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14236
Study 27846903 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy with concomitant standard chemotherapy (up to 66 Gy RBE, six fractions of 2 Gy RBE per week)
Number of subjects: 0
Study 27846903 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy with concomitant standard chemotherapy (up to 66 Gy RBE, six fractions of 2 Gy RBE per week)
Number of subjects: 0
Study 27846903 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0
Study 27846903 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study 24001888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg + methotrexate (MTX)
Number of subjects: 592
Study 24001888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study 24163957 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D supplements (500 mg carbonate calcium plus 200 IU vitamin D3) for 9 weeks
Number of subjects: 49
Study 24163957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 20858943 — intervention group
Group type: EXPERIMENTAL
Intervention: Specified describing style in accordance with ATLAS
Number of subjects: 26
Study 20858943 — intervention group
Group type: COMPARATOR
Intervention: Traditional method used in clinic
Number of subjects: 26
Study 18513691 — intervention group
Group type: EXPERIMENTAL
Intervention: Central pancreatic-head resection (CPHR)
Number of subjects: 100
Study 18513691 — intervention group
Group type: COMPARATOR
Intervention: Quality-of-life (QOL) assessment after CPHR
Number of subjects: 100
Study 16167418 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (TC) cream
Number of subjects: 585
Study 14603516 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium with higher pH and sodium lauryl sulphate (SLS) in dissolution medium
Number of subjects: 0
Study 14603516 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium with lower pH and higher SLS concentration
Number of subjects: 0
Study 14603516 — intervention group
Group type: EXPERIMENTAL
Intervention: New testing conditions using USP Apparatus II at 100 rpm in 0.1 N HCl followed by 0.05 M phosphate buffer with 75 mM SLS
Number of subjects: 0
Study 10935667 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 1000
Study 10935667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 9060789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray applied in the surgical wound
Number of subjects: 60
Study 9060789 — intervention group
Group type: COMPARATOR
Intervention: Routine pain relief (not specified)
Number of subjects: 60
Study 9060789 — intervention group
Group type: COMPARATOR
Intervention: Nurses' ability to predict pain
Number of subjects: 60
Study 9060789 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' ability to predict pain
Number of subjects: 60
Study 9060789 — intervention group
Group type: COMPARATOR
Intervention: Age as a factor in pain perception
Number of subjects: 60
Study 9060789 — intervention group
Group type: COMPARATOR
Intervention: Preoperative anxiety
Number of subjects: 60
Study 9060789 — intervention group
Group type: COMPARATOR
Intervention: Malignant diagnoses
Number of subjects: 60
Study 2052637 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 48
Study 2052637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic
Number of subjects: 48
Study 2052637 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral antibiotics
Number of subjects: 48
Study 6829321 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 1000 mg twice a day for three days
Number of subjects: 215
Study 6829321 — intervention group
Group type: COMPARATOR
Intervention: Co-trimazine 90 mg/sulphadiazine 410 mg, 2 tablets initially, then 1 tablet twice daily for three days
Number of subjects: 215
Study 6829321 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 215
Study 6829321 — intervention group
Group type: COMPARATOR
Intervention: Co-trimazine
Number of subjects: 215
Study 30795944 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 104
Study 30795944 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 104
Study 29990488 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab 75 mg
Number of subjects: 477
Study 29990488 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab 125 mg
Number of subjects: 477
Study 29990488 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab 200 mg
Number of subjects: 477
Study 29990488 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab 700 mg
Number of subjects: 477
Study 29990488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 27091604 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-assisted HBHRT
Number of subjects: 60
Study 27091604 — intervention group
Group type: COMPARATOR
Intervention: Control condition (independent HBHRT)
Number of subjects: 60
Study 24865417 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 10 Hz (n = 12)
Number of subjects: 24
Study 24865417 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (n = 12)
Number of subjects: 24
Study 22278631 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of leflunomide 20 mg
Number of subjects: 24
Study 22278631 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of leflunomide 20 mg
Number of subjects: 24
Study 20832344 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT (n=104)
Number of subjects: 204
Study 20832344 — intervention group
Group type: EXPERIMENTAL
Intervention: DE (n=100)
Number of subjects: 204
Study 20832344 — intervention group
Group type: COMPARATOR
Intervention: Both SPECT and DE
Number of subjects: 204
Study 16439867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa (PEG-IFN) with ribavirin (R)
Number of subjects: 108